pHEMA-nHA Encapsulation and Delivery of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute

Li, Xinning; Xu, Jianwen; Filion, Tera M.; Ayers, David C.; Song, Jie

doi:10.1007/s11999-012-2644-5

Cited by 14 publications

(14 citation statements)

References 38 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pHEMA-nHA-vancomycin composite with 50 wt% nHA and 4.8 or 0 wt% vancomycin was prepared as previously reported [17,27]. Briefly, distilled hydrogel monomer 2-hydroxyethyl methacrylate (HEMA) was crosslinked with 2 wt% ethylene glycol dimethacrylate and ethylene glycol by aqueous radical initiators ammonium persulfate and sodium metabisulfite in the presence of 50 wt% hydroxyapatite (Alfa Aesar, Ward Hill, MA, USA) and 4.8 wt% vancomycin powder (Hospira Inc, Lake Forest, IL, USA).…”

Section: Methodsmentioning

confidence: 99%

“…Our previous study showed that upon 4 and 48 hours equilibration in water, about 80% and about 50% of the preencapsulated vancomycin remains within the graft, respectively [17]. Grafts with 0 wt% vancomycin were equilibrated in water for 48 hours prior to use.…”

Section: Methodsmentioning

confidence: 99%

“…When loaded with a single dose of 400 ng recombinant human bone morphogenetic protein-2/7 heterodimer (rhBMP-2/7) and press-fit into a 5-mm rat femoral segmental defect, the composite facilitated both the formation of fully bridged bony callus in 8 to 12 weeks and the restoration of torsional rigidity by 12 weeks [8]. Furthermore, up to 4.8 wt% vancomycin can be encapsulated within pHEMA-nHA without significantly compromising the structural integrity or the elasticity of the composite graft [17]. Recombinant human bone morphogenetic protein-2 (rhBMP-2), approved by the FDA for spine fusions and tibial fractures [3,7,9], can also be absorbed and released in a localized and sustained manner along with vancomycin with retained bioactivities in vitro [17].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, up to 4.8 wt% vancomycin can be encapsulated within pHEMA-nHA without significantly compromising the structural integrity or the elasticity of the composite graft [17]. Recombinant human bone morphogenetic protein-2 (rhBMP-2), approved by the FDA for spine fusions and tibial fractures [3,7,9], can also be absorbed and released in a localized and sustained manner along with vancomycin with retained bioactivities in vitro [17].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Vancomycin-bearing Synthetic Bone Graft Delivers rhBMP-2 and Promotes Healing of Critical Rat Femoral Segmental Defects

Skelly¹,

Lange²,

Filion³

et al. 2014

Clin Orthop Relat Res

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vancomycin-bearing Synthetic Bone Graft Delivers rhBMP-2 and Promotes Healing of Critical Rat Femoral Segmental Defects

Skelly¹,

Lange²,

Filion³

et al. 2014

Clin Orthop Relat Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast to this study, most researches have explored the release of proteins from delivery systems at 37 °C and often over a shorter time period (27,28). In fact, during the loading and characterization of the release of rhBMP-2, it is important to ensure that the protein is always in its active form.…”

Section: Loading and Release Of Rhbmp-2mentioning

confidence: 97%

A new biocompatible delivery scaffold containing heparin and bone morphogenetic protein 2

Thanyaphoo

Kaewsrichan

2016

Acta Pharmaceutica

View full text Add to dashboard Cite

A new biocompatible delivery scaffold containing heparin and bone morphogenetic protein 2Silicon-substituted calcium phosphate (Si-CaP) was developed in our laboratory as a biomaterial for delivery in bone tissue engineering. It was fabricated as a 3D-construct of scaffolds using chitosan-trisodium polyphosphate (TPP) cross-linked networks. In this study, heparin was covalently bonded to the residual -NH 2 groups of chitosan on the scaffold applying carbodiimide chemistry. Bonded heparin was not leached away from scaffold surfaces upon vigorous washing or extended storage. Recombinant human bone morphogenetic protein 2 (rhBMP-2) was bound to conjugated scaffolds by ionic interactions between the negatively charged SO 4 2-clusters of heparin and positively charged amino acids of rhBMP-2. The resulting scaffolds were inspected for bone regenerative capacity by subcutaneous implanting in rats. Histological observation and mineralization assay were performed after 4 weeks of implantation. Results from both in vitro and in vivo experiments suggest the potential of the developed scaffolds for bone tissue engineering applications in the future.

show abstract

A review on carrier systems for bone morphogenetic protein‐2

Agrawal

Sinha

2016

J Biomed Mater Res

View full text Add to dashboard Cite

Bone morphogenetic protein-2 (BMP-2) has unique bone regeneration property. The powerful osteoinductive nature makes it considered as second line of therapy in nonunion bone defect. A large number of carriers and delivery systems made up of different materials have been investigated for controlled and sustained release of BMP-2. The delivery systems are in the form of hydrogel, microsphere, nanoparticles, and fibers. The carriers used for the delivery are made up of metals, ceramics, polymers, and composites. Implantation of these protein-loaded carrier leads to cell adhesion, degradation which eventually releases the drug/protein at site specific. But, problems like ectopic growth, lesser protein delivery, inactivation of the protein are reported in the available carrier systems. Therefore, it is need of an hour to modify the available carrier systems as well as explore other biomaterials with desired properties. In this review, all the reported carrier systems made of metals, ceramics, polymers, composites are evaluated in terms of their processing conditions, loading capacity and release pattern of BMP-2. Along with these biomaterials, the attempts of protein modification by adding some functional group to BMP-2 or extracting functional peptides from the protein to achieve the desired effect, is also evaluated. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 904-925, 2017.

show abstract

pHEMA-nHA Encapsulation and Delivery of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute

Abstract: The elasticity, osteoconductivity, and rhBMP-2/vancomycin delivery characteristics of pHEMA-nHA may benefit orthopaedic reconstructions or fusions with enhanced safety and efficiency and reduced infection risk.

Cited by 14 publications

References 38 publications

Vancomycin-bearing Synthetic Bone Graft Delivers rhBMP-2 and Promotes Healing of Critical Rat Femoral Segmental Defects

Vancomycin-bearing Synthetic Bone Graft Delivers rhBMP-2 and Promotes Healing of Critical Rat Femoral Segmental Defects

A new biocompatible delivery scaffold containing heparin and bone morphogenetic protein 2

A review on carrier systems for bone morphogenetic protein‐2

Contact Info

Product

Resources

About